JP7612658B2 - 抗ms4a4a抗体、及びその使用方法 - Google Patents
抗ms4a4a抗体、及びその使用方法 Download PDFInfo
- Publication number
- JP7612658B2 JP7612658B2 JP2022506146A JP2022506146A JP7612658B2 JP 7612658 B2 JP7612658 B2 JP 7612658B2 JP 2022506146 A JP2022506146 A JP 2022506146A JP 2022506146 A JP2022506146 A JP 2022506146A JP 7612658 B2 JP7612658 B2 JP 7612658B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024228136A JP2025060826A (ja) | 2019-07-31 | 2024-12-25 | 抗ms4a4a抗体、及びその使用方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881187P | 2019-07-31 | 2019-07-31 | |
| US62/881,187 | 2019-07-31 | ||
| US201962892467P | 2019-08-27 | 2019-08-27 | |
| US62/892,467 | 2019-08-27 | ||
| US201962947449P | 2019-12-12 | 2019-12-12 | |
| US62/947,449 | 2019-12-12 | ||
| US202062960606P | 2020-01-13 | 2020-01-13 | |
| US62/960,606 | 2020-01-13 | ||
| US202063057142P | 2020-07-27 | 2020-07-27 | |
| US63/057,142 | 2020-07-27 | ||
| PCT/US2020/044335 WO2021022083A2 (en) | 2019-07-31 | 2020-07-30 | Anti-ms4a4a antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024228136A Division JP2025060826A (ja) | 2019-07-31 | 2024-12-25 | 抗ms4a4a抗体、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542964A JP2022542964A (ja) | 2022-10-07 |
| JP2022542964A5 JP2022542964A5 (cg-RX-API-DMAC7.html) | 2023-08-07 |
| JP7612658B2 true JP7612658B2 (ja) | 2025-01-14 |
Family
ID=72139691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506146A Active JP7612658B2 (ja) | 2019-07-31 | 2020-07-30 | 抗ms4a4a抗体、及びその使用方法 |
| JP2024228136A Withdrawn JP2025060826A (ja) | 2019-07-31 | 2024-12-25 | 抗ms4a4a抗体、及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024228136A Withdrawn JP2025060826A (ja) | 2019-07-31 | 2024-12-25 | 抗ms4a4a抗体、及びその使用方法 |
Country Status (20)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746476A1 (en) | 2018-01-31 | 2020-12-09 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
| EP3746484A4 (en) | 2018-01-31 | 2021-11-17 | Alector LLC | ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF |
| PH12022550239A1 (en) | 2019-07-31 | 2022-12-19 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| AU2023314795A1 (en) * | 2022-07-29 | 2025-03-06 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
| CN119497721A (zh) * | 2022-07-29 | 2025-02-21 | 艾莱克特有限责任公司 | 转铁蛋白受体抗原结合结构域及其用途 |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| CN116789821A (zh) * | 2022-12-07 | 2023-09-22 | 南方医科大学南方医院 | Ms4a4a作为靶点或抗ms4a4a单克隆抗体在制备治疗结直肠癌的药物中的应用 |
| AU2024370996A1 (en) | 2023-10-30 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2002251692A1 (en) | 2000-12-08 | 2002-08-19 | Duke University | Identification of novel ms4a gene family members expressed by hematopoietic cells |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| GB0324888D0 (en) * | 2003-10-24 | 2003-11-26 | Novartis Ag | Organic compounds |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| AU2005255024C1 (en) | 2004-06-14 | 2010-09-09 | The Board Of Trustees Of The University Of Illinois | Antibodies binding to CD34+/CD36+ fetal but not to adult cells |
| CN101001879A (zh) * | 2004-06-14 | 2007-07-18 | 伊利诺伊大学董事会 | 与胎儿而非成体cd34+/cd36+细胞结合的抗体 |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| WO2008029290A2 (en) * | 2006-09-07 | 2008-03-13 | Universidad De Salamanca | Identification of cancer stem cells using genetic markers |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2108701A1 (en) * | 2008-04-10 | 2009-10-14 | Ganymed Pharmaceuticals AG | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
| WO2010059543A1 (en) * | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| CN104774264B (zh) | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN115960235A (zh) * | 2015-08-28 | 2023-04-14 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| US20190321443A1 (en) | 2016-02-16 | 2019-10-24 | President And Fellows Of Harvard College | Modulators of MS4A activity |
| CN105759057A (zh) * | 2016-04-12 | 2016-07-13 | 上海凯璟生物科技有限公司 | 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法 |
| MY205541A (en) * | 2017-08-03 | 2024-10-25 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EP3746476A1 (en) | 2018-01-31 | 2020-12-09 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
| EP3746484A4 (en) | 2018-01-31 | 2021-11-17 | Alector LLC | ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF |
| PH12022550239A1 (en) | 2019-07-31 | 2022-12-19 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
-
2020
- 2020-07-30 PH PH1/2022/550239A patent/PH12022550239A1/en unknown
- 2020-07-30 MX MX2022001260A patent/MX2022001260A/es unknown
- 2020-07-30 WO PCT/US2020/044335 patent/WO2021022083A2/en not_active Ceased
- 2020-07-30 KR KR1020227006203A patent/KR20220058540A/ko not_active Withdrawn
- 2020-07-30 CR CR20220078A patent/CR20220078A/es unknown
- 2020-07-30 PE PE2022000171A patent/PE20220487A1/es unknown
- 2020-07-30 MY MYPI2022000549A patent/MY208743A/en unknown
- 2020-07-30 EP EP20757743.8A patent/EP4003519A2/en active Pending
- 2020-07-30 NZ NZ785401A patent/NZ785401A/en unknown
- 2020-07-30 BR BR112022001733A patent/BR112022001733A2/pt unknown
- 2020-07-30 US US16/943,123 patent/US11667699B2/en active Active
- 2020-07-30 JP JP2022506146A patent/JP7612658B2/ja active Active
- 2020-07-30 TW TW114103602A patent/TW202519558A/zh unknown
- 2020-07-30 AU AU2020321969A patent/AU2020321969A1/en not_active Abandoned
- 2020-07-30 TW TW109125889A patent/TWI874431B/zh active
- 2020-07-30 CN CN202411885372.7A patent/CN119954954A/zh active Pending
- 2020-07-30 CA CA3145885A patent/CA3145885A1/en active Pending
- 2020-07-30 CN CN202080062076.0A patent/CN114341181B/zh active Active
-
2022
- 2022-01-18 IL IL289952A patent/IL289952A/en unknown
- 2022-01-28 CO CONC2022/0000832A patent/CO2022000832A2/es unknown
- 2022-01-28 CL CL2022000230A patent/CL2022000230A1/es unknown
- 2022-02-25 EC ECSENADI202215044A patent/ECSP22015044A/es unknown
-
2023
- 2023-05-01 US US18/310,207 patent/US20240076362A1/en active Pending
-
2024
- 2024-12-25 JP JP2024228136A patent/JP2025060826A/ja not_active Withdrawn
Non-Patent Citations (3)
| Title |
|---|
| Immunology and Cell Biology,2015年,pp.1-13,DOI: 10.1038/icb.2015.48 |
| Immunology and Cell Biology,2017年,Vol.95,pp.611-619,doi:10.1038/icb.2017.18 |
| membrane-spanning 4-domains subfamily A member 4A isoform 1 [Homo sapiens],NCBI Reference Sequence: NP_683876.1, NCBI,2019年05月02日,pp.1-3,https://www.ncbi.nlm.nih.gov/protein/23110995?sat=47&satkey=82929062 [検索日:2024/07/01] |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114341181B (zh) | 2025-01-07 |
| IL289952A (en) | 2022-03-01 |
| JP2025060826A (ja) | 2025-04-10 |
| CR20220078A (es) | 2022-06-24 |
| JP2022542964A (ja) | 2022-10-07 |
| KR20220058540A (ko) | 2022-05-09 |
| WO2021022083A3 (en) | 2021-03-11 |
| PH12022550239A1 (en) | 2022-12-19 |
| US20240076362A1 (en) | 2024-03-07 |
| TWI874431B (zh) | 2025-03-01 |
| CL2022000230A1 (es) | 2022-10-07 |
| US20210079074A1 (en) | 2021-03-18 |
| ECSP22015044A (es) | 2022-03-31 |
| CN119954954A (zh) | 2025-05-09 |
| EP4003519A2 (en) | 2022-06-01 |
| MY208743A (en) | 2025-05-27 |
| PE20220487A1 (es) | 2022-04-04 |
| TW202120547A (zh) | 2021-06-01 |
| AU2020321969A1 (en) | 2022-03-17 |
| MX2022001260A (es) | 2022-04-18 |
| CN114341181A (zh) | 2022-04-12 |
| US11667699B2 (en) | 2023-06-06 |
| BR112022001733A2 (pt) | 2022-06-28 |
| CA3145885A1 (en) | 2021-02-04 |
| WO2021022083A2 (en) | 2021-02-04 |
| TW202519558A (zh) | 2025-05-16 |
| NZ785401A (en) | 2025-11-28 |
| CO2022000832A2 (es) | 2022-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7486636B2 (ja) | 抗ms4a4a抗体及びその使用方法 | |
| US20240076362A1 (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| US20230303681A1 (en) | Anti-tmem106b antibodies and methods of use thereof | |
| US12215149B2 (en) | Anti-MS4A6A antibodies and methods of use thereof | |
| WO2024086796A1 (en) | Anti-ms4a4a antibodies with amyloid-beta therapies | |
| US20240174746A1 (en) | Anti-tmem106b antibodies and methods of use thereof | |
| HK40063237A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| HK40036037A (en) | Anti-ms4a6a antibodies and methods of use thereof | |
| HK40034438A (zh) | 抗ms4a4a抗体及其使用方法 | |
| HK40036920A (en) | Anti-tmem106b antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20220907 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20220914 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230728 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230728 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230830 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241003 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241126 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241225 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7612658 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |